The serine-threonine kinase Pim-1 is an established oncogene in lymphomagenesis, where it shows dramatic cooperativity in tumor induction with the Myc oncogene. The mechanisms of Pim-1-induced tumorigenicity and the basis for its cooperativity with Myc are largely unknown. Recent studies have shown that Pim-1 is overexpressed in a significant proportion of human prostate cancers and prostatic intraepithelial neoplasia (PIN) lesions. We have recently found that chronic overexpression of Pim-1 in human prostate and breast epithelial cell lines leads to chromosomal instability. Our hypothesis is that Pim-1 overexpression dysregulates expression of mitotic molecules including Cyclin B1, disrupting accurate chromosomal segregation and cytokinesis, culminating in chromosomal instability (CIN). CIN is a common feature of human malignancies, and plays a major role in the generation of genetic abnormalities in tumors. In this proposal, our goals are to elucidate the mechanisms of regulation of Cyclin B1 and mitotic checkpoint molecules by Pim-1 and to establish the role of these molecular alterations in Pim-1-induced chromosomal instability and tumorigenesis. In addition, we will establish and characterize a novel prostate-specific Pim-1 transgenic mouse model to validate these ideas in vivo. Work will be conducted according to the following Specific Aims:
Aim 1 : To elucidate the mechanism(s) underlying altered mitotic regulation and CIN in Pim-1 overexpressing cells.
Aim 2 : To elucidate the roles of Pim-1 and Pim-1-induced chromosomal instability in prostate tumorigenesis by using human prostate cell lines and transgenic mice.
Aim 3 : To test the hypothesis that Pim-1 and Myc cooperate to promote prostate tumorigenesis through the use of human prostate cell lines and transgenic mice. These studies should enhance our understanding of the molecular basis for genomic instability in prostate cancer, establish if Pim-1 is a valid molecular target for prostate cancer therapy and generate new models with relevance to the human disease. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA123484-01A2
Application #
7322682
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Spalholz, Barbara A
Project Start
2007-08-01
Project End
2012-05-31
Budget Start
2007-08-01
Budget End
2008-05-31
Support Year
1
Fiscal Year
2007
Total Cost
$291,406
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pathology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Anker, Jonathan F; Mok, Hanlin; Naseem, Anum F et al. (2018) A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. J Vis Exp :
Anker, Jonathan F; Naseem, Anum F; Mok, Hanlin et al. (2018) Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 9:1591
Unno, Kenji; Roh, Meejeon; Yoo, Young A et al. (2017) Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. Oncotarget 8:51264-51276
Njoroge, Rose N; Unno, Kenji; Zhao, Jonathan C et al. (2017) Organoids model distinct Vitamin E effects at different stages of prostate cancer evolution. Sci Rep 7:16285
Kim, Ji-Young; Yu, Jindan; Abdulkadir, Sarki A et al. (2016) KAT8 Regulates Androgen Signaling in Prostate Cancer Cells. Mol Endocrinol 30:925-36
Yoo, Young A; Roh, Meejeon; Naseem, Anum F et al. (2016) Bmi1 marks distinct castration-resistant luminal progenitor cells competent for prostate regeneration and tumour initiation. Nat Commun 7:12943
Carneiro, Benedito A; Meeks, Joshua J; Kuzel, Timothy M et al. (2015) Emerging therapeutic targets in bladder cancer. Cancer Treat Rev 41:170-8
Kirschner, Austin N; Wang, Jie; van der Meer, Riet et al. (2015) PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst 107:
van der Meer, Riet; Song, Ha Yong; Park, Seong-Hoon et al. (2014) RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. Clin Cancer Res 20:3211-21
Holder, Sheldon L; Abdulkadir, Sarki A (2014) PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance. Curr Cancer Drug Targets 14:105-14

Showing the most recent 10 out of 23 publications